ProPhase Labs, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
ProPhase Labs, Inc. (PRPH) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $265.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-06-01.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2026-06-01
- ProPhase Labs, Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2025 was $265.00K.
- ProPhase Labs, Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2024 was $0.00.
- ProPhase Labs, Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2020 was $159.00K, a 9.66% increase from fiscal 2019.
- ProPhase Labs, Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2019 was $145.00K, a 40.33% decline from fiscal 2018.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $265.00K 10-K · filed 2026-06-01 | |
| 2024-12-31 | $0.00 10-K · filed 2026-06-01 | |
| 2020-12-31 | $159.00K 10-K · filed 2021-03-31 | |
| 2019-12-31 | $145.00K 10-K · filed 2021-03-31 | |
| 2018-12-31 | $243.00K 10-K · filed 2020-03-26 | |
| 2017-12-31 | -$193.00K 10-K · filed 2019-03-26 | -$91.00K 10-K · filed 2018-03-28 |
| 2016-12-31 | $14.00K 10-K/A · filed 2018-08-20 | |
| 2015-12-31 | $53.00K 10-K/A · filed 2018-08-20 | |
| 2014-12-31 | $168.00K 10-K · filed 2017-02-24 | |
| 2013-12-31 | $62.00K 10-K · filed 2016-03-29 | |
| 2012-12-31 | $43.00K 10-K · filed 2015-03-27 | |
| 2011-12-31 | $48.00K 10-K · filed 2014-03-27 | $47.00K 10-K · filed 2013-03-28 |
| 2010-12-31 | -$143.00K 10-K · filed 2013-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |